Polycystic Ovarian Syndrome and Health Volunteers
Conditions
Interventions
Group 1. Control (22 volunteers): three placebo capsules (paraffin) will be administered orally daily for 16 weeks.
Group 2. Calcium (22 volunteers): three calcium carbonate capsules will be administ
Dietary supplement
SP6.051.227
Sponsors
Universidade Federal de Minas Gerais - UFMG
Universidade Federal de Minas Gerais - UFMG
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Clinical trial: women with medical diagnosis of Polycystic Ovarian Syndrome; age between 18 and 40 years.
Exclusion criteria
Exclusion criteria: Type II diabetes; autoimmune disease; adrenal, renal and hepatic diseases; thyroid disorders; cancer or tumors; acute inflammatory disease; hyperprolactinemia; hypogonadism and pregnancy. Volunteers treated with the following medications will also be excluded: steroid and non-steroidal anti-inflammatories; isotretinoin; cyclosporin; antiretrovirals; insulin; metformin and oral contraceptives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Mean difference of at least 5 in the HOMA-B index between supplemented patients and placebo group. - Mean difference of at least 100 ng / ml in CRP dosages between supplemented patients and placebo group. - Mean difference of at least 2.5 mmol / l in nitric oxide dosages between supplemented patients and placebo group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are not expected | — |
Countries
Brazil
Contacts
Public ContactJéssica Tosatti
Universidade Federal de Minas Gerais - UFMG
Outcome results
None listed